The nation of Zimbabwe has declined a substantial US health deal worth $367m (272 million pounds) over five years because of Washington's insistence on confidential biological samples.
The decision was revealed after a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "skewed".
An official spokesman later clarified that the US was demanding access to health data for research and commercial gain while was not willing to guarantee the resulting advantages from future medical innovations.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further negotiations to find a agreement acceptable to both sides so the nation's vital HIV programme can continue.
Wider Context
This development comes after a similar situation in Kenya, where a court halted a related deal with the US after legal challenges were filed about the safety of citizens' health data.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
According to statements, 16 African countries have so far signed these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our people if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining systems already established through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage future global health emergencies.
"This system is intended to ensure that when a country contributes its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "are not meant as hostility towards the US," he added.
"We welcome further discussions with our US partners on how future collaboration might be designed in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts stated it acknowledged the official position, but suggested that negotiations need to persist since a large portion of the nation's HIV programmes relied on international support.
"Where technical issues arise, such as those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it said.
This impasse underscores the complex debate between receiving much-needed international aid and protecting a country's data in an ever more interconnected world.